These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

805 related articles for article (PubMed ID: 31763115)

  • 41. Modulation of Gut Microbiota Through Dietary Intervention in Neuroinflammation and Alzheimer's and Parkinson's Diseases.
    Ayten Ş; Bilici S
    Curr Nutr Rep; 2024 Jun; 13(2):82-96. PubMed ID: 38652236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disease mechanisms as subtypes: Microbiome.
    Bonvegna S; Cilia R
    Handb Clin Neurol; 2023; 193():107-131. PubMed ID: 36803806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intestinal Pathology and Gut Microbiota Alterations in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Mouse Model of Parkinson's Disease.
    Lai F; Jiang R; Xie W; Liu X; Tang Y; Xiao H; Gao J; Jia Y; Bai Q
    Neurochem Res; 2018 Oct; 43(10):1986-1999. PubMed ID: 30171422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson's Disease.
    Fitzgerald E; Murphy S; Martinson HA
    Front Neurosci; 2019; 13():369. PubMed ID: 31068777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Parkinson's disease and the gastrointestinal microbiome.
    Lubomski M; Tan AH; Lim SY; Holmes AJ; Davis RL; Sue CM
    J Neurol; 2020 Sep; 267(9):2507-2523. PubMed ID: 31041582
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of a high saturated fatty acid diet on the intestinal microbiota modification and associated impacts on Parkinson's disease development.
    de Queiroz Cavalcanti SA; de Almeida LA; Gasparotto J
    J Neuroimmunol; 2023 Sep; 382():578171. PubMed ID: 37562163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease.
    Vascellari S; Palmas V; Melis M; Pisanu S; Cusano R; Uva P; Perra D; Madau V; Sarchioto M; Oppo V; Simola N; Morelli M; Santoru ML; Atzori L; Melis M; Cossu G; Manzin A
    mSystems; 2020 Sep; 5(5):. PubMed ID: 32934117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Implications of the Gut Microbiome in Parkinson's Disease.
    Elfil M; Kamel S; Kandil M; Koo BB; Schaefer SM
    Mov Disord; 2020 Jun; 35(6):921-933. PubMed ID: 32092186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Brain-gut-microbiota axis in Parkinson's disease: A historical review and future perspective.
    Dong S; Sun M; He C; Cheng H
    Brain Res Bull; 2022 Jun; 183():84-93. PubMed ID: 35245613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson's disease.
    Li Q; Meng LB; Chen LJ; Shi X; Tu L; Zhou Q; Yu JL; Liao X; Zeng Y; Yuan QY
    Front Neurol; 2023; 14():1185375. PubMed ID: 37305758
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unravelling the potential of gut microbiota in sustaining brain health and their current prospective towards development of neurotherapeutics.
    Banerjee A; Pradhan LK; Sahoo PK; Jena KK; Chauhan NR; Chauhan S; Das SK
    Arch Microbiol; 2021 Aug; 203(6):2895-2910. PubMed ID: 33763767
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.
    Liu J; Xu F; Nie Z; Shao L
    Front Cell Infect Microbiol; 2020; 10():570658. PubMed ID: 33194809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The interplay between gut microbiota and the brain-gut axis in Parkinson's disease treatment.
    Jia X; Wang Q; Liu M; Ding JY
    Front Neurol; 2024; 15():1415463. PubMed ID: 38867886
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of functional food components on gut health.
    Wan MLY; Ling KH; El-Nezami H; Wang MF
    Crit Rev Food Sci Nutr; 2019; 59(12):1927-1936. PubMed ID: 29381385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gut Microbial Metabolites in Parkinson's Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment.
    Liang Y; Cui L; Gao J; Zhu M; Zhang Y; Zhang HL
    Mol Neurobiol; 2021 Aug; 58(8):3745-3758. PubMed ID: 33825149
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gut microbiota and host metabolism in liver cirrhosis.
    Usami M; Miyoshi M; Yamashita H
    World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies.
    Zhang X; Tang B; Guo J
    Transl Neurodegener; 2023 Dec; 12(1):59. PubMed ID: 38098067
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Connecting the immune system, systemic chronic inflammation and the gut microbiome: The role of sex.
    Rizzetto L; Fava F; Tuohy KM; Selmi C
    J Autoimmun; 2018 Aug; 92():12-34. PubMed ID: 29861127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of Gut Microbiota-Brain Axis by Probiotics, Prebiotics, and Diet.
    Liu X; Cao S; Zhang X
    J Agric Food Chem; 2015 Sep; 63(36):7885-95. PubMed ID: 26306709
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review.
    Nair AT; Ramachandran V; Joghee NM; Antony S; Ramalingam G
    J Neurogastroenterol Motil; 2018 Jan; 24(1):30-42. PubMed ID: 29291606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.